Tweet
Am J Stem Cell 2013;2(2):95-107 www.AJSC.us /ISSN:2160-4150/AJSC1305001
Review Article
The development of hematopoietic and mesenchymal stem cell transplantation as an effective treatment for multiple sclerosis
Jameson P Holloman1*, Calvin C Ho1*, Arushi Hukki1*, Jennifer L Huntley1*, G Ian Gallicano1
1Department of Biochemistry and Molecular & Cellular Biology, Georgetown University School of Medicine, 3900 Reservoir Rd. NW, Washington DC 20057, USA. *Contributed equally to this manuscript. Received May 28, 2013; Accepted June 12, 2013; Epub June 30, 2013; Published July 15, 2013
Abstract: This article examines the current use and future implications of stem cell therapy in treating Multiple Scle- rosis (MS). MS is the most common neurological disease in young adults, affecting approximately two million people worldwide. Currently there is no cure for MS. The standard treatment of MS involves disease-modifying drugs, which work to alleviate the symptoms of MS. However, these drugs carry adverse side effects and are ineffective in pre- venting disease progression in many MS patients. Hematopoietic stem cell transplantation (HSCT) was first used in 1995 to treat patients with severe rapidly progressing MS. The HSCT treatment protocol has evolved into a less intense conditioning regimen that is currently demonstrating efficacy in treating patients with variable disease se- verity—with best results in early-stage rapidly progressing MS patients with active CNS inflammation. Mesenchymal stem cell therapy (MSCT) is an experimental stem cell therapy currently undergoing clinical trials. Animal models and early clinical trials have shown promise that MSCT might be a low risk treatment to precipitate neuroregenera- tion and immunomodulation in MS patients. Specifically, neuroprogenitor and placental-derived mesenchymal stem cells offer the best hope for a practical treatment for MS. Stem cell therapy, and perhaps a combinatorial therapeutic approach, holds promise for a better treatment for MS.
Full article (PDF)
http://scholar.google.com/scholar_ur...oi=scholaralrt
Review Article
The development of hematopoietic and mesenchymal stem cell transplantation as an effective treatment for multiple sclerosis
Jameson P Holloman1*, Calvin C Ho1*, Arushi Hukki1*, Jennifer L Huntley1*, G Ian Gallicano1
1Department of Biochemistry and Molecular & Cellular Biology, Georgetown University School of Medicine, 3900 Reservoir Rd. NW, Washington DC 20057, USA. *Contributed equally to this manuscript. Received May 28, 2013; Accepted June 12, 2013; Epub June 30, 2013; Published July 15, 2013
Abstract: This article examines the current use and future implications of stem cell therapy in treating Multiple Scle- rosis (MS). MS is the most common neurological disease in young adults, affecting approximately two million people worldwide. Currently there is no cure for MS. The standard treatment of MS involves disease-modifying drugs, which work to alleviate the symptoms of MS. However, these drugs carry adverse side effects and are ineffective in pre- venting disease progression in many MS patients. Hematopoietic stem cell transplantation (HSCT) was first used in 1995 to treat patients with severe rapidly progressing MS. The HSCT treatment protocol has evolved into a less intense conditioning regimen that is currently demonstrating efficacy in treating patients with variable disease se- verity—with best results in early-stage rapidly progressing MS patients with active CNS inflammation. Mesenchymal stem cell therapy (MSCT) is an experimental stem cell therapy currently undergoing clinical trials. Animal models and early clinical trials have shown promise that MSCT might be a low risk treatment to precipitate neuroregenera- tion and immunomodulation in MS patients. Specifically, neuroprogenitor and placental-derived mesenchymal stem cells offer the best hope for a practical treatment for MS. Stem cell therapy, and perhaps a combinatorial therapeutic approach, holds promise for a better treatment for MS.
Full article (PDF)
http://scholar.google.com/scholar_ur...oi=scholaralrt